US biogenerics mart to reach $2B by 2016
Amgen, with biologic agents sales at over $14.0 billion, and Genentech, number two in the sector with more than $9.0 billion turnover in 2006, are bracing themselves for heavy pressure from biogeneric manufacturers, according to a new report from Decision Resources. This says Amgen's products will be eroded by biogeneric sales in both the USA and Europe. Genentech products such as Rituxan/MabThera (rituximab) and Herceptin (trastuzumab) represent windfall opportunities for biogeneric hopefuls.
The report also reveals that, with the expected launch of biogeneric TNF-alpha inhibitors in 2012, the US biogeneric market will expand substantially through 2016 and reach a total of more than $2.0 billion in annual sales. Biogeneric TNF-alpha inhibitors for rheumatoid arthritis, alone, will generate $700.0 million in sales by 2016, says Decision Resources.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze